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ABSTRACT
Conditional survival (CS) provides a prognosis of patients who have already 
survived several years after treatment. We investigated CS in Barcelona Clinic Liver 
Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC) patients treated with hepatic 
arterial infusion chemotherapy (HAIC) with or without concurrent radiotherapy (CRT). 
A total of 181 patients diagnosed with HCC who were treated with HAIC with or 
without CRT between 2011 and 2015 were retrospectively reviewed. Overall survival 
(OS) and CS were calculated and a subgroup analysis was performed. The 1- and 
5-year survival rates of all patients were 57.0% and 24.3%. OS was significantly 
higher in patients with BCLC stage B than BCLC stage C patients. Patients who 
achieved disease control after treatment also showed longer OS than who did not 
respond to treatment. Provided that the patient had already survived for 0, 1, 2, and 
3 years, the CS estimates of surviving an additional 2 years were 35.6%, 55.1%, 
82.0%, and 77.4%, respectively. A subgroup analysis was performed to compare 
BCLC stage B and C patients and revealed that CS has a tendency to increase and the 
difference in CS between two groups decreased over time. CS reflects the change of 
prognosis over time and may provide a more accurate prognosis and hopeful message 
to patients who have already survived with treatment.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most 
common cancer in the world and the second most common 
cause of cancer-related mortality [1]. The incidence of 
HCC is high in countries where hepatitis B virus (HBV) 
infection is endemic, such as southeast Asia and sub-
Saharan Africa [2]. In Korea, the incidence of HCC 
is declining, but HCC is still one of the main causes of 
cancer-related deaths. Although early-stage HCC patients 
have a good prognosis, with a 60–70% 5-year survival 
rate, only 30–60% of HCC patients are diagnosed at 
an early stage [3, 4]. Most HCC patients diagnosed in 
advanced stage have extensive tumor burden, vascular 
invasion, extrahepatic spread, and/or decompensated 
liver function. Patients with advanced HCC have a poor 
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prognosis, with 5-year survival rates of 10.7% in locally 
advanced stage patients and 3.1% in patients with distant 
metastasis [5].
Cancer staging and risk stratification are required 
to determine the optimal treatment strategy and to 
improve treatment outcomes in HCC patients. The 
Barcelona Clinic Liver Cancer (BCLC) staging system, 
which incorporates the patient’s performance status, 
tumor burden, and liver function, is widely accepted 
and used among several staging systems [6, 7]. Patients 
with advanced HCC are classified as BCLC stage B 
or C; these patients are not candidates for curative 
treatments, such as surgical resection or radiofrequency 
ablation (RFA). For this reason, transhepatic arterial 
chemoembolization (TACE) or systemic therapy with 
sorafenib are recommended for BCLC stage B/C HCC 
patients [8]. However, there are some discrepancies in 
treatment strategies because of regional differences 
in HCC (i.e., the etiology) and other diversities (e.g., 
diagnosis and staging) secondary to a lack of high-level 
evidence [4].
Many efforts have been made to treat advanced 
HCC patients. Hepatic arterial infusion chemotherapy 
(HAIC) has proven to be both effective and safe [9–14]. 
HAIC can achieve increased local drug concentrations 
at the tumor while reducing systemic exposure and 
side effects. Therefore, HAIC has been considered a 
useful palliative therapeutic option for advanced HCC 
patients. Concurrent chemoradiation therapy (CCRT) 
was recently introduced. In our institution, localized 
CCRT followed by HAIC has been used to treat 
advanced HCC without extrahepatic metastasis and has 
shown promising results [15]. Some patients treated 
with CCRT (HAIC with CRT) exhibit good treatment 
responses and conversion from advanced to resectable 
HCC [16–18].
Advanced HCC patients who exhibit a favorable 
treatment response with CCRT (or HAIC) and have 
already survived several years after treatment have a 
different probability of survival than is estimated at the 
time of diagnosis. In these patients, prognosis is more 
accurately described using conditional survival (CS) 
analysis [19]. CS provides a prognosis of patients who 
have already survived several years after treatment and 
is a useful tool to dynamically adjust to individualized 
survival. A more accurate individual prognosis derived 
from CS estimates would be important in clinical practice 
and in research. Conditional survival estimates have been 
published for patients with various cancers [20–22] and 
HCC with curative treatments [23, 24]. However, CS data 
from advanced HCC patients with palliative treatment are 
limited.
The present study explored how CS probability 
changes over time according to different prognostic 
variables, focusing on BCLC stage B/C HCC patients 
treated with HAIC with or without CRT.
RESULTS
Patient characteristics 
Table 1 lists the baseline characteristics of all 181 
patients. The median age was 55 years (range, 28–82 years) 
and 151 (83.4%) patients were males. The most common 
etiology of HCC was HBV infection (n = 153, 84.5%). 
The median radiologic tumor size at diagnosis was 9 cm 
(range, 2–20 cm), and up to 5 masses were found (median, 
1; range, 1–5). The median AFP, albumin, and total bilirubin 
levels were 1444 ng/mL (range, 0.34–120000 ng/mL), 
3.9 g/dL (range, 2.0–4.9 g/dL), and 0.9 mg/dL (range, 0.3–
28.3 mg/dL), respectively. In total, 159 (87.8%) patients 
with preserved liver function were in Child-Pugh class A 
and 22 (12.2%) patients were in Child-Pugh class B. Sixty-
three (34.8%) patients were BCLC stage B and 118 (65.2%) 
patients were BCLC stage C. Approximately 60.8% of 
patients had vascular invasion at diagnosis. Although 
42 (23.2%) patients were treated with HAIC only, most 
patients (139, 76.8%) were treated with HAIC and CRT.
Treatment efficacy and patient actuarial overall 
survival 
The median follow-up period was 11.1 months (range, 
0.4–65.3 months). During this period, 107 (59.1%) patients 
died. the 1-, 3- and 5- year survival rates were 57.0%, 31.4%, 
and 24.3%, respectively (Figure 1). Treatment response of 
HAIC with or without CRT is summarized in Table 2. 69 
patients (38.1%) showed partial response (PR), 50 patients 
showed stable disease (SD) and 50 (27.6%) patients showed 
disease progression (PD). Among all subjects, 38.1% of 
patients experienced the objective response and disease 
control rate was 52.5%. The median OS was significantly 
lower in uncontrolled patients than patients who achieved 
disease control after HAIC with or without CRT (6.4 months 
versus 38.6 months, p < 0.001; Figure 2).
Table 3 lists actuarial survival rates, in relationship 
with patient characteristics. The median OS was 
significantly lower in BCLC stage C patients than stage 
B patients (12.8 versus 24.9 months, p = 0.012). Patients 
in Child-Pugh class A (p < 0.001), TNM stage II/III (p < 
0.001) and those without vascular invasion (p = 0.03) had 
significantly higher survival rates than in patients with 
Child-Pugh class B, TNM stage IV and vascular invasion. 
Younger patients and non-B-viral HCC patients tended to 
have higher survival rates at every time point, but age, 
gender, HCC etiology, and AFP level at diagnosis did not 
significantly affect actuarial survival rates. 
Patient survival according to the Hong Kong 
Liver Cancer staging system
A new HCC staging system was developed by 
Yau T. et al. in 2014 [25]. This Hong Kong Liver Cancer 
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Figure 1: Kaplan-Meier survival curve of actuarial overall survival of the entire study population.
Table 1: Baseline characteristics of all patients
Variables
Age, years 55 (28–82)
Sex, Male/Female 151/30 
Etiology, HBV/Other 153/28
Radiologic tumor size at diagnosis, cm 9 (2–20)
Tumor number at diagnosis 1 (1–5)
AFP at diagnosis, ng/ml 1444 (0.34–120000)
Prothronbin time-INR 1.06 (0.85–1.67)
Albumin (g/dL) 3.9 (2.0–4.9)
Total bilirubin (mg/dL) 0.9 (0.3–28.3)
Platelet count (103/μL) 185 (37–650)
Child-Pugh, A/B 159/22
BCLC, B/C 63/118
TNM stage, II/III/IV 35/67/79
Positive vascular invasion 110 (60.8%)
Treatment modality
 HAIC 42 (23.2%)
 HAIC + CRT 139 (76.8%)
*Variables are expressed as median (range) or n (%).
*HBV, Hepatitis B virus; INR, International normalized ratio; BCLC, Barcelona Clinic Liver Cancer; HAIC, Hepatic arterial 
infusion chemotherapy; CRT, Concurrent radiotherapy.
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(HKLC) staging system subdivides BCLC stage B and C 
patients and recommends more aggressive treatment than 
the BCLC algorithm. BCLC stage B group patients were 
distributed from HKLC stage I to III, and BCLC stage C 
group patients were distributed from HKLC stage II to V. 
The median OS of HKLC stage II (IIa and IIb), III (IIIa and 
IIIb), and IV (IVa and IVb) patients was in 31.2~33.4, 
5.5~12.5, and 1.9~4.0 months, respectively [25].
Survival analysis was performed to evaluate 
the validity of the HKLC staging system in this study 
population and to compare the treatment outcomes of 
our institution (HAIC ± CRT) with the HKLC treatment 
algorithm. The median OS of HKLC stage II, III and IV 
patients in our study population was 29.1, 13.2, and 10.2 
months, respectively (p < 0.001; Figure 3). The difference 
in OS was statistically significant according to the HKLC 
Table 2: Treatment response, objective response rate and disease control rate of all patients
Variables
Treatment response
 Complete response 0
 Partial response 69 (38.1%)
 Stable disease 50 (27.6%)
  ≥ 16 weeks 26 (14.4%)
  < 16 weeks 24 (13.2%)
 Disease progression 50 (27.6%)
 Could not be evaluated 12 (6.6%)
Objective response rate 38.1%
Disease control rate 52.5%
Figure 2: Kaplan-Meier survival curves of overall survival according to the treatment response.
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stage. Thus, we verified the validity of the HKLC staging 
system in our study population and the non-inferiority of 
treatment outcomes of our institution.
Conditional survival 
To predict the effects of BCLC stage and other 
variables at different time points during the follow-up, the 
2-year CS probability after 1, 2 and 3 years was estimated in 
patients treated with HAIC ± CRT (Table 4). The probability 
of surviving an additional 2 years, given that the patient had 
already survived for 1, 2, and 3 years, was 55.1%, 82.0%, 
and 77.4%, respectively, in the entire study population. 
Both BCLC stage B and C patients tended to have an 
increased 2-year CS. The 2-year CS of 0, 1, 2, and 3 years 
in BLCL stage B patients was 52.4%, 65.7%, 82.3%, and 
90.0%, respectively, and that in BCLC stage C patients 
was 26.9%, 48.5%, 81.8%, and 65.0%, respectively 
(Figure 4A). Standardized differences in the 2-year CS 
between BCLC B and C groups revealed a tendency to 
decrease. Standardized differences at 0, 1, 2, and 3 years 
were 0.54, 0.35, 0.01, and 0.63, respectively, indicating 
that the BCLC stage of patients at diagnosis does not 
affect patient survival more than 2 years after treatment. 
Other factors that reflect tumor aggressiveness, such as 
TNM stage and the presence of vascular invasion, had a 
Table 3: Actuarial overall survival rates of patients in relationship to patients’ characteristics
Variables
Patients Survival
1 yr 2 yr 3 yr 4 yr 5 yr P
All patients (n = 181) 57.0% 35.6% 31.4% 29.2% 24.3% -
Age 0.239
 < 65 (n = 137) 58.9% 38.0% 33.9% 32.5% 26.4%
 ≥ 65 (n = 44) 50.8% 29.1% 24.3% 19.4% 19.4%
Gender 0.529
 Male (n = 151) 58.2% 35.7% 33.1% 31.7% 25.6%
 Female (n = 30) 51.5% 34.8% 24.9% 19.9% 19.9%
Etiology 0.057
 HBV (n = 153) 53.8% 31.5% 27.8% 27.8% 22.0%
 Other (n = 28) 74.2% 58.5% 51.2% 43.9% 43.9%
Child-Pugh < 0.001
 A (n = 159) 61.3% 38.3% 33.4% 33.4% 27.8%
 B (n = 22) 26.0% 15.6% 15.6% 5.2% 5.2%
BCLC 0.012
 B (n = 63) 65.6% 52.4% 43.1% 43.1% 38.8%
 C (n = 118) 52.4% 26.9% 25.4% 22.0% 16.5%
TNM < 0.001
 II/III (n = 102) 67.6% 50.2% 42.4% 40.4% 31.6%
 IV (n = 79) 43.0% 17.1% 17.1% 15.0% 15.0%
Vascular invasion 0.03
 No (n = 71) 60.9% 51.2% 42.1% 42.1% 37.9%
 Yes (n = 110) 54.5% 27.1% 25.5% 22.1% 16.6%
AFP 0.12
 < 400 (n = 77) 65.1% 40.9% 36.3% 34.1% 20.8%
 > 400 (n = 104) 50.8% 31.5% 27.5% 25.4% 25.4%
Disease control < 0.001
 Controlled (n = 95) 85.1% 57.7% 51.5% 49.3% 39.9%
 Uncontrolled (n = 86) 26.8% 11.9% 9.9% 7.9% 2.4%
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similar tendency to BCLC stage (Figure 4B and 4C). For 
example, the 2-year CS rates of patients in TNM stage II/
III were higher than 20% compared with stage IV patients 
at 1 year after treatment (62.7% versus 39.8%; d = 0.47). 
However, after 2 years, the CS rate was similar between 
the two groups and standardized differences were lower 
than that at 1 year after treatment (d = −0.20 and −0.34 at 
2 and 3 years after treatment, respectively). 
In contrast, treatment response to HAIC ± CRT and 
baseline liver function did not exhibit a similar change 
in 2-year CS or standardized differences. Patients who 
experienced disease control showed better 2-year CS in 
every time points than patients who had uncontrolled 
disease (57.7%, 60.5%, 85.4% and 77.5% versus 
11.9%, 36.9%, 66.4% and 24.2% at 0, 1, 2, and 3 years, 
respectively). The standardized differences between two 
groups did not decrease over time. (d = 1.10, 0.49, 0.46 
and 1.26 at 0, 1, 2, and 3 years, respectively). Patients 
in Child-Pugh class A also had a better 2-year CS than 
more decompensated patients (38.3%, 54.5%, 87.2%, and 
83.2% versus 15.6%, 60.0%, 33.3%, and 33.3% at 0, 1, 2, 
and 3 years, respectively) and the standardized differences 
did not reveal a tendency to decrease over time (d = 0.53, 
−0.11, 1.32, and 1.17 at 0, 1, 2, and 3 years, respectively). 
Although age and HCC etiology did not exhibit a 
statistically significant difference in actuarial survival rate, 
younger patients and non-B-viral patients had a tendency to 
have a better 2-year CS than older and B-viral HCC patients.
DISCUSSION
We found that tumor characteristics known to 
affect a patient’s actuarial survival, such as BCLC stage, 
TNM stage, and vascular invasion, did not affect CS after 
2 years of treatment. Patients with more aggressive tumor 
features who were classified as advanced (higher) stage 
were expected to have a poor prognosis, and did exhibit 
a significantly lower actuarial OS rate than early stage 
patients. However, advanced stage patients who exhibited 
a favorable treatment response with HAIC ± CRT for the 
first 2 years had similar CS estimates as patients with less 
aggressive tumor features.
Figure 3: Kaplan-Meier survival curves of overall survival according to the Hong Kong Liver Cancer (HKLC) stage.
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Table 4: 2-year conditional survival rates in relationship to patients’ characteristics
Variables
Estimated 2-year conditional survival
At diagnosis
1 year after 
treatment
2 years after 
treatment
3 years after 
treatment
All patients (n = 181) 35.6% 55.1% 82.0% 77.4%
Age
 < 65 (n = 137) 38.0% 57.6% 85.5% 77.9%
 ≥ 65 (n = 44) 29.1% 47.8% 66.7% 79.8%
 d 0.19 0.20 0.45 −0.05 
Gender
 Male (n = 151) 35.7% 56.9% 88.8% 77.3%
 Female (n = 30) 34.8% 48.3% 57.2% 79.9%
 d 0.02 0.17 0.76 −0.06 
Etiology
 HBV (n = 153) 31.5% 51.7% 88.3% 79.1%
 Other (n = 28) 58.5% 69.0% 75.0% 85.7%
 d -0.56 –0.36 0.35 −0.17 
Child-Pugh
 A (n = 159) 38.3% 54.5% 87.2% 83.2%
 B (n = 22) 15.6% 60.0% 33.3% 33.3%
 d 0.53 –0.11 1.32 1.17 
BCLC
 B (n = 63) 52.4% 65.7% 82.3% 90.0%
 C (n = 118) 26.9% 48.5% 81.8% 65.0%
 d 0.54 0.35 0.01 0.63 
TNM
 II/III (n = 102) 50.2% 62.7% 80.5% 74.5%
 IV (n = 79) 17.1% 39.8% 87.7% 87.7%
 d 0.75 0.47 −0.20 −0.34 
Vascular invasion
 No (n = 71) 51.2% 69.1% 82.2% 90.0%
 Yes (n = 110) 27.1% 46.8% 81.5% 65.1%
 d 0.51 0.46 0.02 0.63 
AFP
 < 400 (n = 77) 40.9% 55.8% 83.4% 57.3%
 > 400 (n = 104) 31.5% 54.1% 80.6% 92.4%
 d 0.20 0.03 0.07 −0.88 
Disease control
 Controlled (n = 95) 57.7% 60.5% 85.4% 77.5%
 Uncontrolled (n = 86) 11.9% 36.9% 66.4% 24.2%
 d 1.10 0.49 0.46 1.26
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To date, treatment outcomes and prognosis of 
cancer patients are typically described as actuarial OS 
or 5-year survival rate. However, these measures only 
reflect a patient’s information at the time of diagnosis and 
represent the survival data of the entire patient population. 
Conversely, CS provides useful information on the 
patient’s prognosis that is adjusted for the time the patient 
already survived. CS provides cancer patients with more 
individualized prognostic information and determines 
how their prognosis evolves over time. Merrill et al. 
demonstrated that CS has a tendency to increase over time 
in various cancers, and that an increment in CS is notable 
in advanced stage and more lethal types of cancer (i.e., lung 
and pancreatic cancer) [26]. This result has been observed 
for many cancer entities in various studies [20–24, 27–29]. 
Therefore, CS information can be considered relevant and 
may provide hope to patients, clinicians, and researchers 
interested in the probability of surviving additional years.
The prognosis of advanced-stage HCC patients 
(including locally advanced and unresectable HCC) had 
been reported as dismal. The median survival of untreated 
HCC patients with BCLC stage C is 7 months [30] and 
only 2.7 months in those with portal vein thrombosis 
(PVT) [31]. Although sorafenib is a recommended 
treatment option for patients, it is not widely used as first-
line treatment because of its marginal survival benefit, 
relatively high costs, and low tolerability with frequent 
adverse events [32]. Furthermore, the presence of PVT 
is a significant limitation of HCC treatment because it is 
considered a contraindication for transplantation, curative 
resection, and TACE in treatment guidelines [8, 33]. There 
is also a problem in establishing treatment strategy for 
BCLC stage B patients. Although BCLC stage B includes 
an extremely diverse set of patients, BCLC staging 
system recommends only TACE as treatment modality. To 
overcome this problem, studies had been conducted for the 
appropriate treatment for BCLC stage B patients. Bolondi 
et al. showed poor prognosis in patients beyond the up-
to-7 criteria and suggested the use of sorafenib or clinical 
trials for patients in substage B2 and B3 [34]. Yamakado 
Figure 4: 2-year conditional survival rates according to (A) BCLC stage, (B) TNM stage and (C) vascular invasion. The CS difference 
between two groups was decreased over time.
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et al. revealed that BCLC stage B patients who had ≥ 5 
tumors or > 7 cm sized tumor showed markedly reduced 
treatment response to TACE [35]. In this study population, 
most patients exhibited advanced HCC at diagnosis. 
Approximately 65.2% (n = 118) of patients were in BCLC 
stage C and 60.8% (n = 110) of patients had vascular 
(portal vein [PV] and hepatic vein [HV]) tumor invasion. 
Even in BCLC stage B patients of this study population 
(n = 63) who did not showed any vascular invasion, most of 
patients had multiple or massive, infiltrative tumors larger 
than 5 cm that were not suitable for loco-regional therapy.
To treat advanced HCC patients, our institution used 
a combination therapy of HAIC and CRT on the basis of 
previous favorable treatment results [15]. Although patients 
who had a diffuse or multifocal bi-lobal tumor could not be 
treated with radiotherapy to avoid whole-liver irradiation, 
which could cause serious adverse effects, patients with 
PVT (including the main portal vein) were successfully 
treated with HAIC ± CRT and exhibited tolerable treatment-
related side effects. Similar to previous treatment outcomes, 
HAIC ± CRT yielded notable treatment outcomes in this 
study. The median survival of BCLC stage C patients in 
this study group was 12.8 months and that in patients with 
vascular invasion was 13.2 months. HAIC allows the local 
delivery of chemotherapeutic agents in high concentrations 
and maximizes the therapeutic effects of radiation therapy 
with reduced systemic toxicity [10, 36–38]. Excellent 
tumor responses, include down-staging of HCC, could be 
achieved by HAIC ± CRT. Therefore, it could be a useful 
treatment modality in advanced HCC patients. 
We also reviewed the medical records regarding 
tumor characteristics at diagnosis and treatment outcomes 
of long-term survivors who survived for 2 or more 
years. In total, 34 patients survived for 2 or more years. 
Among them, 32 (94.1%) patients exhibited favorable 
treatment responses after HAIC ± CRT: 18 patients 
eventually achieved successful down-staging followed by 
curative operation (including 4 patients who underwent 
liver transplantation) and 1 patient achieved a complete 
response (no residual tumor on imaging) after HAIC 
with CRT and consecutive additional HAIC. Of the 
long-term survivors, 50% of patients were BCLC stage 
C patients and 50% had vascular invasion of the tumor 
at diagnosis. Considering the poor prognosis of advanced 
HCC patients, these proportions are meaningful. We 
previously demonstrated that BCLC stage and vascular 
invasion of the tumor at diagnosis does not affect patient 
survival more than 2 years after treatment. Therefore, 
a good prognosis could be expected for patients who 
have favorable treatment responses, even for those with 
advanced HCC at diagnosis. 
However, CS in patients with poor baseline liver 
function did not tend to improve over time. Similar 
results have been observed in previous studies on CS in 
HCC patients [23, 24]. Those studies found that baseline 
liver function has a constant effect on CS over time. 
Additionally, a previous study on the subclassification of 
BCLC stage found that patients with poor liver function 
had worse survival outcomes than patients with preserved 
liver function [39]. In the present study, the proportion 
of Child-Pugh class B patients in long-term (> 2 years) 
survivors was only 3% (3/34), and 72.7% (16/22) of Child-
Pugh class B patients died within 1 year after treatment. 
The OS and CS of Child-Pugh class A patients was 
significantly higher than class B patients and standardized 
differences did not decrease over time between Child-
Pugh class A and B patients. Therefore, we conclude that 
underlying liver function has a constant effect on CS over 
time and we should emphasize that sufficient preserved 
liver function at treatment initiation is an important factor 
for long-term prognosis.
Our study had several strengths. First, to the best 
of our knowledge, this study is the first to estimate CS in 
advanced HCC patients treated with HAIC with/without 
CRT, which is a non-curative loco-regional therapy. 
Compared to previous studies, patients in this study group 
had more advanced-stage HCC and worse underlying liver 
function [23, 24]. However, the CS estimate increased over 
time in both BCLC stage B and C patients with notable 
treatment outcomes. Therefore, clinicians can provide a 
hopeful message that prognosis can be improved through 
loco-regional therapy, even in patients with advanced-
stage HCC at the time of diagnosis. Second, the new HCC 
staging system, the HKLC staging system, was validated. 
The HKLC staging system was effective at predicting 
patient survival. The HKLC staging system, based on data 
from HBV-related HCC patients with relatively preserved 
basal liver function, subdivides the BCLC stage and 
emphasizes more aggressive treatment than the BCLC 
staging system. The OS of patients differed significantly 
according to subdivided HKLC stage II, III, and IV in this 
population. Furthermore, the tendency of CS to increase 
over time was also observed in HKLC stage 2 and 3 
patients. The 2-year CS of 0, 1, and 2 in HKLC stage II 
patients was 56.9%, 68.3%, and 82.3%, respectively, and 
32.4%, 54.2%, and 75.6%, respectively, in HKLC stage III 
patients. The tendency of CS to increase over time has been 
confirmed in different staging systems, suggesting that CS 
estimates can be applied regardless of the staging system.
This study had some limitations. First, it had a 
relatively small sample size and retrospective design. 
The study population did not represent all patients with 
advanced HCC. Second, the follow-up duration was not 
long enough to confirm the long-term data of CS tendency. 
Sufficient follow-up duration and a larger sample size 
providing sufficient long-term survival data would lead 
to more accurate CS estimates. Third, this study did not 
analyze changes in patient quality of life and how these 
affected survival. Although no life-threatening serious 
adverse effects after HAIC with CRT were observed in 
this study population, medical records regarding changes 
in performance status (e.g., ECOG status) or quality of 
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life (e.g., FACT-hep) were insufficient. Finally, due to the 
aggressiveness of the advanced stage HCC, the number 
of survivors declined sharply over time, so subjects to 
be analyzed after years were rapidly decreased. It limits 
clinical implication of this study. Further investigations 
and a well-organized prospective study are needed to 
overcome these limitations.
In conclusion, CS tends to increase over time in 
patients with BCLC stage B/C HCC treated with HAIC 
with or without CRT. CS may provide a more accurate 
prognosis and a more hopeful message to patients who 
have already survived with treatment.
MATERIALS AND METHODS 
Study population
The diagnosis of HCC was based on pathological 
confirmation or the typical appearance of HCC, either 
by two dynamic imaging examinations (computed 
tomography [CT] and magnetic resonance imaging [MRI]) 
or by one dynamic technique combined with elevated 
serum alpha-fetoprotein (AFP) level (> 200 ng/mL). 
The patients were identified using the Severance 
Hospital Hepatocellular Carcinoma Cohort Registry, 
which is an internal Web-based electronic medical record 
that encompasses HCC patients who were treated with 
anticancer therapy at the Severance Hospital, Yonsei 
University College of Medicine, from 2011 to 2015. A 
total of 228 patients were found to have received HAIC 
with or without CRT to treat advanced HCC. The inclusion 
criteria were as follows: (1) 18 years of age or older; (2) at 
least one measurable or evaluable HCC lesion; (3) Eastern 
Cooperative Oncology Group (ECOG) performance status 
≤ 2; (4) no prior antitumor treatment before HAIC with or 
without CRT, such as TACE, surgery or radiofrequency 
ablation; (5) estimated life expectancy ≥ 12 weeks; (6) 
Child-Pugh class A or B; (7) BCLC stage B and C; and (8) 
other adequate organ function (absolute neutrophil count 
≥ 1.5 × 109/L, serum creatinine < 1.5 mg/dL or calculated 
creatinine clearance ≥ 60 mL/min by the Cockcroft and 
Gault formula, aminotransferase level less than 5 times the 
upper limit of normal). Finally, 181 patients were identified 
as eligible patients who met the enrollment criteria. 
This study was approved by the local Institutional 
Review Board and was conducted in accordance with the 
principles set forth in the Declaration of Helsinki. Written 
informed consent was obtained from all patients
Implantation of the port system
 The femoral artery was accessed by experienced 
interventional radiologists using the Seldinger method. 
Arteriography of the celiac trunk and superior mesenteric 
artery was performed to evaluate hepatic arterial 
vascularization and portal vein patency, respectively. After 
detection of the HCC and its feeding artery, the tip of the 
catheter (Port-A-Cath1; Deltac, St. Paul, MN, USA) was 
placed at the common hepatic artery or proper hepatic 
artery under fluoroscopic guidance. The proximal end of 
the catheter was connected to the injection port, which 
was implanted into a subcutaneous pocket in the right iliac 
fossa. To prevent thrombosis of the catheter lumen, 10,000 
units of heparin were infused via the port after each cycle 
of chemotherapy.
Treatment protocols and response evaluation
Patients treated with HAIC and CRT received a 
total radiation dose of 45 Gy in 25 fractions over a period 
of 5 weeks with a concurrent hepatic arterial infusion of 
5-fluorouracil (5-FU; 500 mg/day for 5 h on 5 consecutive 
days through an implanted port system) during the first 
and fifth weeks of radiotherapy. For patients treated 
with HAIC without CRT, 5-FU (500 mg/m2 for 5 h on 
days 1–3) and cisplatin (60 mg/m2 for 2 h on day 2) 
were administered every 4 weeks based on a previously 
described method [15]. In every CRT patient, CT-based 
three-dimensional (3D) treatment planning was performed 
to determine the target volumes, radiation ports, and dose 
prescription. The gross tumor volumes (GTVs) were 
defined as the tumor areas noted on the CT, including 
portal vein thrombosis. A minimum of 5 mm around the 
GTV was included in the clinical target volume. The 
planning target volume was designed so that the margins 
were individualized by observing liver position as well as 
liver movement at the time of simulation. The distance 
of diaphragmatic excursion by respiration, which was 
observed fluoroscopically, was added to determine the 
cranial–caudal margins. Standard localized HAIC and 
CRT protocols were maintained throughout the study 
period. 
After 5 weeks of HAIC with CRT or 2 cycles of HAIC 
without CRT, treatment response was evaluated by CT or 
MRI according to RECIST criteria [40] and consecutive 
treatment such as HAIC or systemic chemotherapy was 
performed according to the patient’s treatment response. 
Objective response was defined as complete response (CR) 
and PR. Disease control was defined as CR, PR, and SD 
that maintained 16 or more weeks. 
Definition of conditional survival
Conditional survival (CS) is derived from the 
biostatistics concept of conditional probability [41] 
and can be calculated from traditional Kaplan-Meier 
or actuarial life table survival data. The mathematical 
definition of CS is expressed as follows: CS (y│x) is the 
probability of surviving for an additional y years, given 
that the patient has already survived x years. Let S(t) 
be the traditional actuarial survival at time t; CS can be 
calculated as: 
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For example, to estimate the 3-year CS for a 
patient who has already survived 2 years, we simply 
divide the survival estimate at t = 3 + 2, S(5) by the 
survival at t = 2, S(2).
Statistical analysis
All statistical analyses were performed using SPSS 
for windows version 23.0 (SPSS Inc., Chicago, IL, USA). 
Student’s t-test was used to compare continuous variables, 
and the chi-square or Fisher’s exact test was used for 
categorical variables. Overall survival (OS) was computed 
from the day treatment began until the most recent follow-
up or death. Survival time and rate were estimated by the 
Kaplan-Meier method, and differences between groups 
were assessed using the log-rank test. A P value < 0.05 
was considered statistically significant. 
The CS differences between groups were compared 
by calculating standardized differences (d), which were 
used in terms of effect size. Standardized differences were 
calculated as follows:
( ) ( )1 1 2
( ) 
/
Pp Pe
d
Pp Pp Pe Pe
−
=
− + −  
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where Pp and Pe denote the proportion of a binary 
baseline variable in two groups [42]. d values less than 0.1 
indicate very small differences between groups; d values 
between 0.1 and 0.3 indicate small differences; d values 
between 0.3 and 0.5 indicate moderate differences; and 
d values greater than 0.5 indicate considerable differences.
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